{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=29", "query": { "intervention": "SC", "page": 29 }, "page_size": 10 }, "pagination": { "page": 29, "page_size": 10, "total_count": 3861, "total_pages": 387, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=30&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SC&page=28&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T04:11:29.951Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05996523", "title": "Phase II Trial of Immunotherapeutic HPV Vaccine PRGN-2009 With Pembrolizumab Before Standard Treatment in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharyngeal Squamous Cell Carcinoma (SCC)" ], "interventions": [ { "name": "PRGN-2009", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "EKG", "type": "DIAGNOSTIC_TEST" }, { "name": "CT", "type": "DIAGNOSTIC_TEST" }, { "name": "PET scan", "type": "DIAGNOSTIC_TEST" }, { "name": "MRI", "type": "DIAGNOSTIC_TEST" }, { "name": "Biopsy", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "DIAGNOSTIC_TEST", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 26, "start_date": "2023-11-07", "completion_date": "2030-07-16", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT05996523" }, { "nct_id": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Non-Small Cell Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "BIOLOGICAL" }, { "name": "Atezolizumab and Recombinant Human Hyaluronidase", "type": "BIOLOGICAL" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Patient Observation", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 336, "start_date": "2027-03-02", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 119, "location_summary": "Beverly Hills, California • Los Angeles, California • Tarzana, California + 99 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Tarzana", "state": "California" }, { "city": "Torrance", "state": "California" }, { "city": "Millville", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT07388524" }, { "nct_id": "NCT07010159", "title": "Phase 2/3 Study of Participants With Recurrent Pericarditis Evaluating the Efficacy and Safety of KPL-387", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Pericarditis", "Pericarditis Acute", "Recurrent Pericarditis" ], "interventions": [ { "name": "KPL-387", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kiniksa Pharmaceuticals International, plc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 325, "start_date": "2025-07-25", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-28", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 33, "location_summary": "Gilbert, Arizona • Phoenix, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07010159" }, { "nct_id": "NCT00125190", "title": "Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Insulin-Like Growth Factor-1 Deficiency", "Growth Disorders" ], "interventions": [ { "name": "rhIGF-1 (mecasermin) for a period of 86 weeks", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ipsen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": null, "sex": "ALL", "summary": "3 Years and older" }, "enrollment_count": 45, "start_date": "2005-07", "completion_date": "2009-01", "has_results": true, "last_update_posted_date": "2020-07-27", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 1, "location_summary": "Brisbane, California", "locations": [ { "city": "Brisbane", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00125190" }, { "nct_id": "NCT03214380", "title": "A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "LY900014", "type": "DRUG" }, { "name": "Insulin Lispro", "type": "DRUG" }, { "name": "Insulin Glargine", "type": "DRUG" }, { "name": "Insulin Degludec", "type": "DRUG" }, { "name": "Metformin", "type": "DRUG" }, { "name": "SGLT2 inhibitor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 933, "start_date": "2017-07-14", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 32, "location_summary": "Fresno, California • La Mesa, California • Lancaster, California + 26 more", "locations": [ { "city": "Fresno", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Santa Clarita", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03214380" }, { "nct_id": "NCT01802892", "title": "Study in Healthy Volunteers, to Evaluate the Safety, Efficacy and Dose Responses of SB-751689 (Ronacaleret)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Transplantation, Stem Cell" ], "interventions": [ { "name": "Ronacaleret 100 mg", "type": "DRUG" }, { "name": "Ronacaleret 400 mg", "type": "DRUG" }, { "name": "Plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2012-11-02", "completion_date": "2013-04-02", "has_results": false, "last_update_posted_date": "2017-06-07", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01802892" }, { "nct_id": "NCT04909801", "title": "A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Abatacept", "type": "DRUG" }, { "name": "Adalimumab", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 338, "start_date": "2021-09-15", "completion_date": "2027-09-01", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 14, "location_summary": "Fullerton, California • Los Alamitos, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Fullerton", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Cumberland", "state": "Maryland" }, { "city": "Hagerstown", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04909801" }, { "nct_id": "NCT01292265", "title": "A 12 Week Study to Assess Changes in Joint Inflammation Using Ultrasonography in Patients With Rheumatoid Arthritis (RA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "UCB Pharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2011-02", "completion_date": "2012-01", "has_results": true, "last_update_posted_date": "2018-08-01", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 6, "location_summary": "Los Angeles, California • Walnut Creek, California • Wheaton, Maryland + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Wheaton", "state": "Maryland" }, { "city": "Voorhees Township", "state": "New Jersey" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01292265" }, { "nct_id": "NCT06376045", "title": "A Phase 2, Dose Ranging Study Assessing Rocatinlimab in Moderate-to-severe Asthma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Rocatinlimab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 317, "start_date": "2024-05-24", "completion_date": "2026-06-23", "has_results": false, "last_update_posted_date": "2026-08-11", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 48, "location_summary": "Bakersfield, California • La Jolla, California • La Palma, California + 42 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "La Palma", "state": "California" }, { "city": "Lancaster", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06376045" }, { "nct_id": "NCT00039377", "title": "Chemotherapy, Imatinib Mesylate, and Peripheral Stem Cell Transplantation in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "tacrolimus", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "etoposide", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "59 Years", "sex": "ALL", "summary": "15 Years to 59 Years" }, "enrollment_count": 58, "start_date": "2002-04", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-10-29T04:11:29.951Z", "location_count": 97, "location_summary": "Atlanta, Georgia • Bloomington, Illinois • Canton, Illinois + 63 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Bloomington", "state": "Illinois" }, { "city": "Canton", "state": "Illinois" }, { "city": "Carthage", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00039377" } ] }